TY - JOUR
T1 - Characterizing functional regional homogeneity (ReHo) as a B-SNIP psychosis biomarker using traditional and machine learning approaches
AU - Ji, Lanxin
AU - Meda, Shashwath A.
AU - Tamminga, Carol A.
AU - Clementz, Brett A.
AU - Keshavan, Matcheri S.
AU - Sweeney, John A.
AU - Gershon, Elliot S.
AU - Pearlson, Godfrey D.
N1 - Funding Information:
This work was supported by the National Institute of Mental Health Grant Nos. MH077851 (to CAT), MH078113 (to MSK), MH077945 (to GDP), MH077852 (to Gunvant K. Thaker), and MH077862 (to JAS). The National Institute of Mental Health had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Funding Information:
JAS has served on advisory boards for Bristol-Myers Squibb, Eli Lilly, Pfizer, Roche, and Takeda, and has received grant support from Janssen. MSK has received research support from Sunovion and GlaxoSmithKline. CAT has served on the advisory board for drug development for Intra-Cellular Therapies, Inc.; has served as an ad hoc consultant for Eli Lilly, Sunovion, Astellas, Pfizer, and Merck; has been a council member and unpaid volunteer for the National Alliance on Mental Illness; and has served as deputy editor for the American Psychiatric Association. All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Information:
This work was supported by the National Institute of Mental Health Grant Nos. MH077851 (to CAT), MH078113 (to MSK), MH077945 (to GDP), MH077852 (to Gunvant K. Thaker), and MH077862 (to JAS). The National Institute of Mental Health had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1
Y1 - 2020/1
N2 - Background: Recently, a biologically-driven psychosis classification (B-SNIP Biotypes) was derived using brain-based cognitive and electrophysiological markers. Here, we characterized a local functional-connectivity measure, regional homogeneity (ReHo), as a biomarker across Biotypes and conventional DSM diagnoses. Methods: Whole-brain ReHo measures of resting-state functional MRI were examined in psychosis patients and healthy controls organized by Biotype and by DSM-IV-TR diagnosis (n = 737). Group-level ANOVA and individual-level prediction models using support vector machines (SVM) were employed to evaluate the discriminative characteristics in comparisons of 1) DSM diagnostic groups, 2) Biotypes, to controls, and 3) within-proband subgroups with each other. Results: Probands grouped by Biotype versus controls showed a unique abnormality pattern: Biotype-1 displayed bidirectional ReHo differences in more widespread areas, with higher ReHo in para-hippocampus, fusiform, inferior temporal, cerebellum, thalamus and caudate, plus lower ReHo in the postcentral gyrus, middle temporal, cuneus, and middle occipital cortex; Biotype-2 and Biotype-3 showed lesser and unidirectional ReHo changes. Among diagnostic groups, only schizophrenia showed higher ReHo versus control values in the inferior/middle temporal area and fusiform gyrus. For within-patient comparisons, Biotype-1 showed characteristic ReHo when compared to Biotype-2 and Biotype-3. SVM results more accurately identified Biotypes than DSM diagnoses. Conclusion: We characterized patterns of ReHo abnormalities across both Biotypes and DSM sub-groups. Both group-level statistical and machine-learning methods were more sensitive in capturing ReHo deficits in Biotypes than DSM. Overall ReHo is a robust psychosis biomarker.
AB - Background: Recently, a biologically-driven psychosis classification (B-SNIP Biotypes) was derived using brain-based cognitive and electrophysiological markers. Here, we characterized a local functional-connectivity measure, regional homogeneity (ReHo), as a biomarker across Biotypes and conventional DSM diagnoses. Methods: Whole-brain ReHo measures of resting-state functional MRI were examined in psychosis patients and healthy controls organized by Biotype and by DSM-IV-TR diagnosis (n = 737). Group-level ANOVA and individual-level prediction models using support vector machines (SVM) were employed to evaluate the discriminative characteristics in comparisons of 1) DSM diagnostic groups, 2) Biotypes, to controls, and 3) within-proband subgroups with each other. Results: Probands grouped by Biotype versus controls showed a unique abnormality pattern: Biotype-1 displayed bidirectional ReHo differences in more widespread areas, with higher ReHo in para-hippocampus, fusiform, inferior temporal, cerebellum, thalamus and caudate, plus lower ReHo in the postcentral gyrus, middle temporal, cuneus, and middle occipital cortex; Biotype-2 and Biotype-3 showed lesser and unidirectional ReHo changes. Among diagnostic groups, only schizophrenia showed higher ReHo versus control values in the inferior/middle temporal area and fusiform gyrus. For within-patient comparisons, Biotype-1 showed characteristic ReHo when compared to Biotype-2 and Biotype-3. SVM results more accurately identified Biotypes than DSM diagnoses. Conclusion: We characterized patterns of ReHo abnormalities across both Biotypes and DSM sub-groups. Both group-level statistical and machine-learning methods were more sensitive in capturing ReHo deficits in Biotypes than DSM. Overall ReHo is a robust psychosis biomarker.
KW - Biological marker
KW - Biotypes
KW - Machine learning
KW - Psychosis
KW - ReHo
KW - Resting-state
UR - http://www.scopus.com/inward/record.url?scp=85070715572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070715572&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2019.07.015
DO - 10.1016/j.schres.2019.07.015
M3 - Article
C2 - 31439419
AN - SCOPUS:85070715572
SN - 0920-9964
VL - 215
SP - 430
EP - 438
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -